You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Reimbursement news and insurance coverage updates.
The genomic test is covered by Medicare for all men with localized prostate cancer being considered for treatment.
The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.
The organization had previously only recommended the use of noninvasive prenatal testing in individuals 35 and older or with other known risk factors.
In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.
The classifiers are considered reasonable and necessary if the patient can tolerate chemotherapy and it's being considered as a treatment for the patient.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.
